Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $31.19 USD
Change Today +0.40 / 1.30%
Volume 108.4K
ADRO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

aduro biotech inc (ADRO) Snapshot

Open
$30.68
Previous Close
$30.79
Day High
$31.45
Day Low
$30.39
52 Week High
04/16/15 - $49.25
52 Week Low
04/30/15 - $24.68
Market Cap
1.9B
Average Volume 10 Days
426.2K
EPS TTM
--
Shares Outstanding
62.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADURO BIOTECH INC (ADRO)

Related News

No related news articles were found.

aduro biotech inc (ADRO) Related Businessweek News

No Related Businessweek News Found

aduro biotech inc (ADRO) Details

Aduro BioTech, Inc., a clinical-stage immuno-oncology company, focuses on the development of technology platforms designed to stimulate robust and durable immune responses against cancer. Its lead product candidate is CRS-207, which is in a Phase IIb clinical trial for the treatment of metastatic pancreatic cancer and unresectable malignant pleural mesothelioma. The company’s cyclic dinucleotides product candidates are synthetic small molecule immune modulators that target and activate Stimulator of Interferon Genes receptor. Aduro BioTech, Inc. has collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.

53 Employees
Last Reported Date: 05/28/15
Founded in 2000

aduro biotech inc (ADRO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $886.6K
Chief Operating Officer
Total Annual Compensation: $585.9K
Chief Scientific Officer
Total Annual Compensation: $584.9K
Compensation as of Fiscal Year 2014.

aduro biotech inc (ADRO) Key Developments

Aduro BioTech, Inc.(NasdaqGS:ADRO) added to Russell 2000 Index

Aduro BioTech, Inc. will be added to Russell 2000 Index

Aduro BioTech, Inc.(NasdaqGS:ADRO) added to Russell 3000 Index

Aduro BioTech, Inc. will be added to the Russell 3000 Index.

Aduro Biotech, Inc. Announces Passing of Immunotherapy Regimen's Futility Analysis in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer

Aduro Biotech, Inc. announced that an independent Data Monitoring Committee (DMC) recommended that the Phase 2b ECLIPSE trial of its novel LADD and GVAX immunotherapies continue as planned without modification based on the successful outcome of a pre-specified futility analysis. The DMC assessment included an evaluation of interim primary efficacy and safety data from over half of the anticipated patient population enrolled in the trial. The randomized, controlled three-arm trial is expected to enroll over 300 patients at 21 clinical trial sites in the United States and Canada to evaluate the safety, immune response and efficacy of the combination immunotherapy of CRS-207 in combination with GVAX Pancreas compared to chemotherapy. The trial also has a treatment arm to evaluate CRS-207 as a monotherapy. The primary endpoint of the trial is overall survival in the primary cohort of patients who have received two or more prior therapies for metastatic disease. A second cohort of patients who have received one prior therapy for metastatic disease is also being evaluated. Last year, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Aduro's pancreatic cancer combination treatment consisting of CRS-207 and GVAX Pancreas. According to the FDA, Breakthrough Therapy designation is for a drug candidate that treats a serious or life-threatening condition for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint over available therapies. Breakthrough Therapy designation was granted based on results from a Phase 2a clinical trial of patients with metastatic pancreatic cancer treated with CRS-207 and GVAX Pancreas. The multi-center trial, which enrolled 93 patients with metastatic pancreatic cancer, demonstrated a statistically significant survival benefit in patients receiving the combination immuno-oncology regimen of CRS-207 and GVAX Pancreas compared to GVAX Pancreas alone. The results were published in the January 2015 issue of the Journal of Clinical Oncology (JCO). Results of the Phase 2a clinical trial published in JCO indicated the median overall survival of Arm A patients receiving the combination regimen of CRS-207 and GVAX Pancreas was 6.1 months compared to 3.9 months for Arm B patients receiving GVAX monotherapy (HR=0.5930, one-sided p=0.0172). One-year survival probability for patients in Arm A was 24% compared with 12% for patients in Arm B. The trial enrolled advanced-stage metastatic pancreatic cancer patients who previously received or refused prior chemotherapy, with most patients having received two or more prior therapies in the metastatic setting. Patients were randomized in a 2:1 ratio to receive two doses of GVAX Pancreas vaccine followed by four doses of CRS-207 (Arm A) or to receive six doses of GVAX Pancreas vaccine alone (Arm B). Clinically stable patients were allowed to receive additional treatment courses. Of the 93 patients enrolled, the most frequent treatment-related Grade 3 or 4 adverse event (AE) was asymptomatic, transient lymphopenia, with three patients experiencing Grade 3 lymphopenia and two patients experiencing Grade 4 lymphopenia. There were no other Grade 4 AEs, and there were no other Grade 3 AEs with frequencies higher than 5% in either arm. The most common Grade 3 AEs were transient lymphopenia, fevers, elevated liver enzymes and fatigue.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADRO:US $31.19 USD +0.40

ADRO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $23.57 USD +0.33
Inovio Pharmaceuticals Inc $7.92 USD -0.22
Novavax Inc $10.88 USD -0.12
Peregrine Pharmaceuticals Inc $1.30 USD +0.01
ZIOPHARM Oncology Inc $11.22 USD -0.40
View Industry Companies
 

Industry Analysis

ADRO

Industry Average

Valuation ADRO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 71.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADURO BIOTECH INC, please visit www.aduro.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.